Pfizer (NYSE:PFE) Trading Up 1.9% – What’s Next?

Pfizer Inc. (NYSE:PFE)’s stock price rose 1.9% on Tuesday . The company traded as high as $29.74 and last traded at $29.64. Approximately 7,338,895 shares changed hands during trading, a decline of 80% from the average daily volume of 37,173,520 shares. The stock had previously closed at $29.08.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Thursday, October 3rd. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Trading Up 0.9 %

The stock has a market capitalization of $166.20 billion, a PE ratio of -494.00, a price-to-earnings-growth ratio of 1.30 and a beta of 0.67. The firm has a 50-day moving average price of $29.02 and a 200-day moving average price of $28.40. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the firm posted $0.67 EPS. The business’s revenue was up 2.1% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.73%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently -2,800.00%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Olistico Wealth LLC bought a new position in Pfizer in the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $29,000. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter valued at about $31,000. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter valued at about $32,000. Finally, Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.